Are you working on your latest research? You have one more week to submit an abstract and present your clinical findings, therapies, or pipeline to a focused international audience.

Did you know that with 64 approved advanced therapy medicinal products (ATMPs) worldwide, the United States, by authorizing 20 ATMPs (11 CTMPs, 7 TEPs, and 2 GTMPs), is the pioneer country in this field? It is followed by South Korea with 15 ATMPs (13 CTMPs and 2 TEPs), the European Union with 9 ATMPs, and Iran with 6 ATMPs.

Make sure your country is represented during the in-person edition of ICLE 2022 on 31 March – 2 April 2022. Send us your important work today and put your country on the lymphocyte еngineering map!

Don’t miss this opportunity to advance your career and share your insights on CAR-T Cell and other lymphocyte engineering therapies at the cornerstone event in the field.

Accepted abstracts will be published in HGT Journal – the premier, multidisciplinary journal covering all aspects of gene therapy – HGT Journal.

Abstract Submission Deadline: 16 November 2021